Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Latest News about Lymphoma

Recent news which mentions Lymphoma

Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Tickers BMY IMTX
Tags Biotech Benzinga Large Cap
From Benzinga
Gilead Sciences: U.S. Military Veteran Battles Lymphoma With Car T-Cell Therapy: Marcus' Story
Tags Gilead NYSE:GILD Lymphoma
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Mom Celebrates Sons' Milestones: Julie's CAR T-cell Therapy Journey
Tags Health & Healthcare NYSE:GILD Lymphoma
From 3BL Media: Corporate Social Responsibility, Energy and Health News
Discover Cord Blood’s Life-Saving Benefits at the 7th Annual Arizona Cord Blood Conference – United by Our Strengths
Tags umbilical cord cancer treatment cord blood
From PRUnderground
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Tickers FATE
Tags Phase 1 Trial lymphoma General
From Benzinga
Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients
Tickers GILD
Tags Benzinga General GILD
From Benzinga
Viracta Therapeutics Posts Data From Lymphoma Trial At ASH Presentation
Tickers VIRX
Tags General Phase 1 Trial lymphoma
From Benzinga
Jazz Posts New Data for ALL/LBL Treatment At ASH 2021 Annual Meeting
Tickers JAZZ
Tags Briefs Biotech lymphoma
From Benzinga
Roche Uncorks Favorable Responses From Mosunetuzumab In Follicular Lymphoma Settings
Tickers RHHBF RHHBY RHHVF
Tags RHHVF lymphoma Phase 1 Trial
From Benzinga
Gilead's Kite Unveils More Data On Yescarta In Second-Line Lymphoma Patients
Tickers GILD
Tags ASH21 Market News Health Care
From Benzinga
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
Tickers BMY
Tags News Phase 3 Trial BMY
From Benzinga
TG Therapeutics Shares Plunge After FDA Plans AdComm Meet For Blood Cancer Candidate
Tickers TGTX
Tags Chronic Lymphocytic Leukemia Biotech Briefs
From Benzinga
Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose
Tickers AFMD
Tags Phase 2 Trial News Market News
From Benzinga
Soligenix To File US Application For Its Lymphoma Photodynamic Therapy In 2H 2022
Tickers SNGX
Tags lymphoma General FDA
From Benzinga
IDI Consulting Supports the Leukemia & Lymphoma Society's Light The Night Walk
Tags United States Pittsburgh Lymphoma
From PRLog
Gilead's Kite Files US Application To Expand Use Of Yescarta In Second-Line Setting
Tickers GILD
Tags FDA News Market News
From Benzinga
BeiGene's Brukinsa Scores FDA Approval For Marginal Zone Lymphoma
Tickers BGNE
Tags FDA Movers Trading Ideas
From Benzinga
Soligenix Stock Moves Higher On US Orphan Drug Tag For T-cell Lymphoma Candidate
Tickers SNGX
Tags Health Care Movers Trading Ideas
From Benzinga
ADC Therapeutics Announces $325M Financing Agreement With HealthCare Royalty
Tickers ADCT
Tags Market News Phase 2 Trial News
From Benzinga
Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
Tickers FATE
Tags General lymphoma Phase 1 Trial
From Benzinga
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
Tickers CLRB
Tags Health Care Market News CLRB
From Benzinga
F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients
Tickers FSTX
Tags Market News News General
From Benzinga
BeiGene's Brukinsa Scores Second Approval In Canada, This Time For Mantle Cell Lymphoma
Tickers BGNE
Tags Health Care Market News News
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.